2024
Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations
Elghazaly H, Azim H, Rugo H, Cameron D, Swain S, Curigliano G, Harbeck N, Tripathy D, Arun B, Aapro M, Piccart M, Cardoso F, Gligorov J, Elghazawy H, Saghir N, Penault‐Llorca F, Perez E, Poortmans P, Abdelaziz H, El‐Zawahry H, Kassem L, Sabry M, Viale G, Al‐Sukhun S, Gado N, Leung J, Elarab L, Cardoso M, Karim K, Foheidi M, Elmaadawy M, Conte P, Selim A, Kandil A, Kamal R, Paltuev R, Guarneri V, Abulkhair O, Zakaria O, Golshan M, Orecchia R, ElMahdy M, Abdel‐Aziz A, Eldin N. Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations. Cancer 2024, 130: 3251-3271. PMID: 38985794, DOI: 10.1002/cncr.35389.Peer-Reviewed Original ResearchBreast cancerNeoadjuvant therapyManagement of early breast cancerEarly breast cancerIndividual patient managementDe-escalation strategiesModified Delphi approachBC expertsPostneoadjuvant treatmentSystemic therapyClinical evidencePatient managementConsensus recommendationsClinical situationsTherapyDe-escalationDelphi approachTherapy outcomeTreatment settingsCancerExpert opinionRecommendationsBreastConsensus
2021
How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk
2017
170P Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysis
Criscitiello C, Golshan M, Barry W, Viale G, Wong S, Santangelo M, Curigliano G. 170P Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysis. Annals Of Oncology 2017, 28: v50-v51. DOI: 10.1093/annonc/mdx362.020.Peer-Reviewed Original Research
2016
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?
Criscitiello C, Curigliano G, Burstein H, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? European Journal Of Surgical Oncology 2016, 42: 1780-1786. PMID: 27825710, DOI: 10.1016/j.ejso.2016.10.011.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsAxillaBreast NeoplasmsClinical Decision-MakingFemaleGenes, BRCA1Genes, BRCA2Genetic Predisposition to DiseaseHereditary Breast and Ovarian Cancer SyndromeHumansLymph Node ExcisionMastectomyMastectomy, SegmentalMedical OveruseNeoadjuvant TherapyPatient PreferenceSurgical OncologyConceptsBreast conservationNeoadjuvant therapyBreast cancerSystemic therapyPathologic complete response rateComplete response rateBreast conservation ratesEffective systemic treatmentPatient-level variablesInvasive surgical approachNeoadjuvant trialsInoperable patientsSurgical overtreatmentSystemic treatmentSurgical approachSurgical benefitsOncology communityResponse ratePatientsTherapyCancerAggressive optionsMastectomySurgeonsConservation rate
2015
Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance).
Golshan M, Cirrincione C, Carey L, Sikov W, Berry D, Burstein H, Overmoyer B, Henry N, Somlo G, Port E, Winer E, Hudis C, Ollila D. Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance). Journal Of Clinical Oncology 2015, 33: 1007-1007. DOI: 10.1200/jco.2015.33.15_suppl.1007.Peer-Reviewed Original Research
2013
Neoadjuvant bevacizumab: Surgical complications of mastectomy with and without reconstruction.
Kansal K, Dominici L, Tolaney S, Isakoff S, Krop I, Smith B, Jiang W, Potler H, Brock J, Winer E, Golshan M. Neoadjuvant bevacizumab: Surgical complications of mastectomy with and without reconstruction. Journal Of Clinical Oncology 2013, 31: 1100-1100. DOI: 10.1200/jco.2013.31.15_suppl.1100.Peer-Reviewed Original ResearchSurgical complicationsAC/TNeoadjuvant bevacizumabNeoadjuvant therapyComplication rateCohort 2Cohort 1Breast cancerExact testImmediate expander/implant reconstructionHER2-negative breast cancerExpander/implant reconstructionOperable breast cancerUse of bevacizumabOverall complication rateRate of complicationsThird of patientsCohort of patientsSingle-arm trialSame healthcare systemFisher's exact testTerms of demographicsNon-randomized dataPostoperative complicationsImplant reconstructionImpact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance).
Ollila D, Berry D, Cirrincione C, Carey L, Amos K, Henry N, Winer E, Hudis C, Golshan M. Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance). Journal Of Clinical Oncology 2013, 31: 501-501. DOI: 10.1200/jco.2013.31.15_suppl.501.Peer-Reviewed Original ResearchNeoadjuvant therapyBCT candidatesCALGB 40601Neoadjuvant chemotherapySystemic therapySurgical resultsBreast surgeonsBreast cancerTumor-free surgical marginsBreast cancer ptsNeoadjuvant systemic therapyOperable breast cancerBreast conservation ratesPhase III trialsAnti-HER2 treatmentModern systemic therapyBreast cancer operationsBCT eligibilityCancer ptsEligible patientsNeoadjuvant trialsTherapy ratesIII trialsSurgical marginsCancer operations
2011
P2-15-01: Surgical Patterns of Care after Magnetic Resonance Imaging in the Academic Setting in Patients with Operable Breast Cancer Treated with Neoadjuvant Systemic Therapy: A Secondary Analysis of TBCRC 017.
De L, Cantor A, Mcguire K, Golshan M, Meric-Bernstam F, Horton J, Nanda R, Amos K, Forero A, Hudis C, Meszoely I, Hwang S. P2-15-01: Surgical Patterns of Care after Magnetic Resonance Imaging in the Academic Setting in Patients with Operable Breast Cancer Treated with Neoadjuvant Systemic Therapy: A Secondary Analysis of TBCRC 017. Cancer Research 2011, 71: p2-15-01-p2-15-01. DOI: 10.1158/0008-5472.sabcs11-p2-15-01.Peer-Reviewed Original ResearchNeoadjuvant systemic therapyT stageMastectomy ratesBreast conservationMRI responseJonckheere-Terpstra testChemotherapy regimenSystemic therapyCancer CenterSurgical patternsSecondary analysisBreast MRIHigher mastectomy ratesPotential response biomarkersT1-T2 patientsUse of mastectomyOperable breast cancerLarger tumor sizeHigher T stageComprehensive cancer centerLogistic regression analysisMagnetic resonance imagingNeoadjuvant chemotherapyNeoadjuvant therapyPreoperative chemotherapy
2009
Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy
Ryan P, Tung N, Isakoff S, Golshan M, Richardson A, Corben A, Smith B, Gelman R, Winer E, Garber J. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. Journal Of Clinical Oncology 2009, 27: 551-551. DOI: 10.1200/jco.2009.27.15_suppl.551.Peer-Reviewed Original ResearchTriple-negative breast cancerClinical partial responseClinical complete responseNeoadjuvant cisplatinNeoadjuvant therapyPulmonary embolismBreast cancerStable diseaseProgressive diseasePathological responseHearing lossWeeks x 4 cyclesTreatment of TNBCSingle-arm phase II trialArm phase II trialCycles of bevacizumabEfficacy of bevacizumabGrade 4 toxicityComplete pathological responseAddition of bevacizumabPhase II trialMetastatic breast cancerEfficacy of chemotherapyNegative breast cancerTissue-based assays